|   News

The under-40s: How does the next generation of biopharma executives view the future?


The young standouts featured here have worked hard to get where they are, and they’re nowhere near finished. If you’re looking for a common theme, it’s about making a difference — in a big way — in how people will deal with disease in the future. Together, they are thinking about groups of millions that all have to be stripped down to one single case at a time.

Michael Gladstone, Principal, Atlas Venture: During his first year in Atlas Venture, Michael Gladstone got really excited about a new cancer treatment called CAR-T. His colleagues, though, didn’t seem so sure.

Read more.